Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2012
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Eyetech Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2011
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Eyetech Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Details : Macugen (Pegaptanib Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Retinopathy.
Product Name : Macugen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2011
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2010
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2010
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2010
Lead Product(s) : Macugen
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
